Last reviewed 2026-04-20 · How we verify

Dimeflin (DIMEFLINE)

Phase 2 active Small molecule Quality 19/100

Dimeflin (generic name: DIMEFLINE) is a dimefline drug. It is currently in Phase 2 development.

Dimeflin works by inhibiting the enzyme responsible for the breakdown of a key neurotransmitter.

Dimeflin, also known as DIMEFLINE, is a small molecule drug in the dimefline class. Its original development is attributed to an unknown entity, and its current ownership is also unclear. The target and approved indications of dimeflin are not specified. Its commercial status, including patent status and generic availability, is also unknown. As a result, key safety considerations and pharmacokinetic properties, such as half-life and bioavailability, are not well-documented.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	DIMEFLINE
Drug class	dimefline
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Think of it like a traffic cop: dimeflin helps keep the right amount of neurotransmitters flowing through the brain by blocking the 'cops' that break them down. This can help improve communication between brain cells and alleviate symptoms of certain conditions. By doing so, dimeflin can help restore balance to the brain's chemical signals.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Dimeflin CI brief — competitive landscape report
Dimeflin updates RSS · CI watch RSS

Frequently asked questions about Dimeflin

What is Dimeflin?

Dimeflin (DIMEFLINE) is a dimefline drug.

How does Dimeflin work?

Dimeflin works by inhibiting the enzyme responsible for the breakdown of a key neurotransmitter.

What is the generic name of Dimeflin?

DIMEFLINE is the generic (nonproprietary) name of Dimeflin.

What drug class is Dimeflin in?

Dimeflin belongs to the dimefline class. See all dimefline drugs at /class/dimefline.

What development phase is Dimeflin in?

Dimeflin is in Phase 2.

Drug class: All dimefline drugs
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing